Industry sponsor intelligence

Bio Genuine (Shanghai) Biotech Co., Ltd.Clinical Pipeline.

Lead-sponsor view of Bio Genuine (Shanghai) Biotech Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.

Total: 1
Recruiting: 0
Active: 0
Completed: 0
Results posted: 0
Avg enrollment: 240

Pipeline overview

Programs by phase and activity.

Velocity

Bio Genuine (Shanghai) Biotech Co., Ltd. trials by start year

Study start year · indexed snapshot

Development

Trials by phase

1phase labels

Early Phase 10

Phase 10

Phase 21

Phase 30

Phase 40

Product	Studies	Early / I	Phase II	Phase III	Phase IV	Active
Cetrorelix →	1	0	1	0	0	0

Active peptide trials

In motion now.

No studies in this snapshot.

Completed trials

Finished registry records.

No studies in this snapshot.

Search sponsor records

All Bio Genuine (Shanghai) Biotech Co., Ltd. studies.

This page groups studies where Bio Genuine (Shanghai) Biotech Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.

1 matching study

Last registry update first

NCT05738382Phase 2

Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures

CetrorelixBio Genuine (Shanghai) Biotech Co., Ltd.Assisted Reproductive Technology · Controlled Ovarian Hyperstimulation

Unknown

Enrollment: 240
Started: Aug 2023
Completion: Dec 2024
Locations: 10
Countries: 1
Updated: Jul 2023

End of 1 results

Recent updates

Latest registry movement.

NCT05738382Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART ProceduresJul 27, 2023